Sphera Funds Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Sphera Funds Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-20,623	Closed	-$299K	–	110
2020 Q1	$299K	Sell	20,623 -40,571	-66%	-$881K	0.04%	73
2019 Q4	$723K	Hold	61,194	–	–	0.06%	82
2019 Q3	$1.54M	Buy	+61,194	New	+$1.77M	0.24%	68
2017 Q4	–	Sell	-3,193	Closed	-$217K	–	155
2017 Q3	$217K	Sell	3,193 -2,327	-42%	-$190K	0.03%	121
2017 Q2	$522K	Buy	5,520 +1,949	+55%	+$224K	0.09%	110
2017 Q1	$513K	Hold	3,571	–	–	0.1%	101
2016 Q4	$453K	Buy	+3,571	New	+$497K	0.11%	92
2015 Q3	–	Sell	-5,881	Closed	-$3.72M	–	142
2015 Q2	$3.72M	Sell	5,881 -309	-5%	-$164K	0.36%	65
2015 Q1	$3.19M	Buy	+6,190	New	+$3.12M	0.33%	75

Other funds holding VIRX

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sphera Funds Management's VIRX Position: Q2 2020 in Review

Sphera Funds Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2020, closing a stake of 20,623 shares — an estimated $299K sold.

Sphera Funds Management first reported a position in VIRX in Q1 2015 and held it in 9 quarters. The position peaked at $3.72M in Q2 2015. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2020.

Sphera Funds Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Sphera Funds Management sold 20,623 Viracta Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $299K.
Sphera Funds Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2015 and held it in 9 quarters.
Sphera Funds Management's Viracta Therapeutics, Inc. Common Stock position peaked at $3.72M in Q2 2015.
41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.